Although RUNX1 mutations are only included as MR genes in ICC, a shorter survival time was observed in patients with AML and RUNX1 mutations than in patients with other MR gene mutations in this study, and it was the second most frequent mutation after TP53 in AML-MR in the 2022 WHO. This evidence concerns the gene RUNX1 and acute myeloid leukemia.